Cristina Ferreira Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cristina Ferreira Almeida has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Amaral
UCIBIO i4HB, Faculdade de Farmácia, Universidade do Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal
8 shared publications - Natércia Teixeira
UCIBIO—Applied Molecular Biosciences Unit, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal
7 shared publications - Georgina Correia-Da-Silva
UCIBIO i4HB, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira 228, 4050-313, Porto, Portugal
6 shared publications - Anne Marie Vinggaard
National Food Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
3 shared publications - Maria João Valente
National Food Institute, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
3 shared publications - Carla Varela
Coimbra Institute for Clinical and Biomedical Research (iCBR), Clinic Academic Center of Coimbra (CACC), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
2 shared publications
Latest Publications
- Open Access
New Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment
Background/Objectives: Endocrine therapies that comprise anti-estrogens and aromatase inhibitors (AIs) are the standard treatment for estrogen receptor-positive (ER+) (Luminal A) breast cancer—the most prevalent subtype. However, the emergence of resistance restricts their success by causing tumor relapse and re-growth, which demands a switch towards other therapeutic approaches in order to minimize or overcome resistance. Indeed, this clinical limitation highlights the search for new molecules to improve cancer treatment. Recently, strategies that address multiple targets have been emerging, and multi-target drugs have the potential to become the future anti-cancer molecules. Our group has been searching for new multi-target compounds, and as part of this, our study aims to understand the anti-cancer and multi-target potential of three new steroidal aromatase inhibitors (AIs): 7α-methylandrost-4-en-17-one (6), 7α-methylandrost-4-ene-3,17-dione (10a) and androsta-4,9(11)-diene-3,17-dione (13). Methods: Their in vitro actions and molecular mechanisms were elucidated in a sensitive ER+ aromatase-overexpressing breast cancer cell line, MCF-7aro cells, as well as in an AI-resistant ER+ breast cancer cell line, LTEDaro cells. Results: All the new AIs (10 µM) prevented the proliferation of MCF-7aro cells by arresting cell cycle progression. Interestingly, all AIs (10 µM) act as androgen receptor (AR) agonists and modulate ER levels, synthesis and signaling to induce the apoptosis of ER+ breast cancer cells. Additionally, these new AIs (10 µM) also re-sensitize resistant cells by promoting apoptosis, offering a therapeutic benefit. Conclusions: Overall, new steroidal polypharmacological compounds have been discovered that, by acting as AIs, ER modulators and AR agonists, impair ER+ breast cancer cell growth. Overall, this study is a breakthrough on drug discovery as it presents new molecules with appealing anti-cancer properties and multi-target action for the treatment of ER+ breast cancer.
Open AccessNew Promising Steroidal Aromatase Inhibitors with Multi-Target Action on Estrogen and Androgen Receptors for Breast Cancer Treatment
Background/Objectives: Endocrine therapies that comprise anti-estrogens and aromatase inhibitors (AIs) are the standard treatment for estrogen receptor-positive (ER+) (Luminal A) breast cancer—the most prevalent subtype. However, the emergence of resistance restricts their success by causing tumor relapse and re-growth, which demands a switch towards other therapeutic approaches in order to minimize or overcome resistance. Indeed, this clinical limitation highlights the search for new molecules to improve cancer treatment. Recently, strategies that address multiple targets have been emerging, and multi-target drugs have the potential to become the future anti-cancer molecules. Our group has been searching for new multi-target compounds, and as part of this, our study aims to understand the anti-cancer and multi-target potential of three new steroidal aromatase inhibitors (AIs): 7α-methylandrost-4-en-17-one (6), 7α-methylandrost-4-ene-3,17-dione (10a) and androsta-4,9(11)-diene-3,17-dione (13). Methods: Their in vitro actions and molecular mechanisms were elucidated in a sensitive ER+ aromatase-overexpressing breast cancer cell line, MCF-7aro cells, as well as in an AI-resistant ER+ breast cancer cell line, LTEDaro cells. Results: All the new AIs (10 µM) prevented the proliferation of MCF-7aro cells by arresting cell cycle progression. Interestingly, all AIs (10 µM) act as androgen receptor (AR) agonists and modulate ER levels, synthesis and signaling to induce the apoptosis of ER+ breast cancer cells. Additionally, these new AIs (10 µM) also re-sensitize resistant cells by promoting apoptosis, offering a therapeutic benefit. Conclusions: Overall, new steroidal polypharmacological compounds have been discovered that, by acting as AIs, ER modulators and AR agonists, impair ER+ breast cancer cell growth. Overall, this study is a breakthrough on drug discovery as it presents new molecules with appealing anti-cancer properties and multi-target action for the treatment of ER+ breast cancer.
- Open Access
- 21 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (9) , 1245
Molecular Targets of Minor Cannabinoids in Breast Cancer: In Silico and In Vitro Studies
Background: Breast cancer therapy has been facing remarkable changes. Classic treatments are now combined with other therapies to improve efficacy and surpass resistance. Indeed, the emergence of resistance demands the development of novel therapeutic approaches. Due to key estrogen signaling, estrogen receptor-positive (ER+) breast cancer treatment has always been focused on aromatase inhibition and ER modulation. Lately, the effects of phytocannabinoids, mainly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have been evaluated in different cancers, including breast. However, Cannabis sativa contains more than 120 phytocannabinoids less researched and understood. Methods: Here, we evaluated, both in silico and in vitro, the ability of 129 phytocannabinoids to modulate important molecular targets in ER+ breast cancer: aromatase, ER, and androgen receptor (AR). Results: In silico results suggested that some cannabinoids may inhibit aromatase and act as ERα antagonists. Nine selected cannabinoids showed, in vitro, potential to act either as ER antagonists with inverse agonist properties, or as ER agonists. Moreover, these cannabinoids were considered as weak aromatase inhibitors and AR antagonists with inverse agonist action. Conclusions: Overall, we present, for the first time, a comprehensive analysis of the actions of the phytocannabinoids in targets of ER+ breast tumors, pointing out their therapeutic potential in cancer and in other diseases.
- 21 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (9) , 1245
Open AccessMolecular Targets of Minor Cannabinoids in Breast Cancer: In Silico and In Vitro Studies
Background: Breast cancer therapy has been facing remarkable changes. Classic treatments are now combined with other therapies to improve efficacy and surpass resistance. Indeed, the emergence of resistance demands the development of novel therapeutic approaches. Due to key estrogen signaling, estrogen receptor-positive (ER+) breast cancer treatment has always been focused on aromatase inhibition and ER modulation. Lately, the effects of phytocannabinoids, mainly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have been evaluated in different cancers, including breast. However, Cannabis sativa contains more than 120 phytocannabinoids less researched and understood. Methods: Here, we evaluated, both in silico and in vitro, the ability of 129 phytocannabinoids to modulate important molecular targets in ER+ breast cancer: aromatase, ER, and androgen receptor (AR). Results: In silico results suggested that some cannabinoids may inhibit aromatase and act as ERα antagonists. Nine selected cannabinoids showed, in vitro, potential to act either as ER antagonists with inverse agonist properties, or as ER agonists. Moreover, these cannabinoids were considered as weak aromatase inhibitors and AR antagonists with inverse agonist action. Conclusions: Overall, we present, for the first time, a comprehensive analysis of the actions of the phytocannabinoids in targets of ER+ breast tumors, pointing out their therapeutic potential in cancer and in other diseases.
- Open Access
In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
Introduction: The third-generation of aromatase inhibitors (AIs)—Exemestane (Exe), Letrozole (Let), and Anastrozole (Ana)—is the main therapeutic approach applied for estrogen receptor-positive (ER+) breast cancer (BC), the most common neoplasm in women worldwide. Despite their success, the development of resistance limits their efficacy. Genistein (G), a phytoestrogen present in soybean, has promising anticancer properties in ER+ BC cells, even when combined with anticancer drugs. Thus, the potential beneficial effects of combining G with AIs were investigated in sensitive (MCF7-aro) and resistant (LTEDaro) BC cells. Methods: The effects on cell proliferation and expression of aromatase, ERα/ERβ, and AR receptors were evaluated. Results: Unlike the combination of G with Ana or Let, which negatively affects the Ais’ therapeutic efficacy, G enhanced the anticancer properties of the steroidal AI Exe, increasing the antiproliferative effect and apoptosis relative to Exe. The hormone targets studied were not affected by this combination when compared with Exe. Conclusions: This is the first in vitro study that highlights the potential benefit of G as an adjuvant therapy with Exe, emphasizing, however, that soy derivatives widely used in the diet or applied as auxiliary medicines may increase the risk of adverse interactions with nonsteroidal AIs used in therapy.
Open AccessIn Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
Introduction: The third-generation of aromatase inhibitors (AIs)—Exemestane (Exe), Letrozole (Let), and Anastrozole (Ana)—is the main therapeutic approach applied for estrogen receptor-positive (ER+) breast cancer (BC), the most common neoplasm in women worldwide. Despite their success, the development of resistance limits their efficacy. Genistein (G), a phytoestrogen present in soybean, has promising anticancer properties in ER+ BC cells, even when combined with anticancer drugs. Thus, the potential beneficial effects of combining G with AIs were investigated in sensitive (MCF7-aro) and resistant (LTEDaro) BC cells. Methods: The effects on cell proliferation and expression of aromatase, ERα/ERβ, and AR receptors were evaluated. Results: Unlike the combination of G with Ana or Let, which negatively affects the Ais’ therapeutic efficacy, G enhanced the anticancer properties of the steroidal AI Exe, increasing the antiproliferative effect and apoptosis relative to Exe. The hormone targets studied were not affected by this combination when compared with Exe. Conclusions: This is the first in vitro study that highlights the potential benefit of G as an adjuvant therapy with Exe, emphasizing, however, that soy derivatives widely used in the diet or applied as auxiliary medicines may increase the risk of adverse interactions with nonsteroidal AIs used in therapy.
- Open Access
An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER+) Breast Cancer: Effects on Sensitive and Resistant Cell Lines
Around 70–85% of all breast cancer (BC) cases are estrogen receptor-positive (ER+). The third generation of aromatase inhibitors (AIs) is the first-line treatment option for these tumors. Despite their therapeutic success, they induce several side effects and resistance, which limits their efficacy. Thus, it is crucial to search for novel, safe and more effective anti-cancer molecules. Currently, multi-target drugs are emerging, as they present higher efficacy and lower toxicity in comparison to standard options. Considering this, this work aimed to investigate the anti-cancer properties and the multi-target potential of the compound 1α,2α-epoxy-6-methylenandrost-4-ene-3,17-dione (Oxy), also designated by Oxymestane-D1, a derivative of Exemestane, which we previously synthesized and demonstrated to be a potent AI. For this purpose, it was studied for its effects on the ER+ BC cell line that overexpresses aromatase, MCF-7aro cells, as well as on the AIs-resistant BC cell line, LTEDaro cells. Oxy reduces cell viability, impairs DNA synthesis and induces apoptosis in MCF-7aro cells. Moreover, its growth-inhibitory properties are inhibited in the presence of ERα, ERβ and AR antagonists, suggesting a mechanism of action dependent on these receptors. In fact, Oxy decreased ERα expression and activation and induced AR overexpression with a pro-death effect. Complementary transactivation assays demonstrated that Oxy presents ER antagonist and AR agonist activities. In addition, Oxy also decreased the viability and caused apoptosis of LTEDaro cells. Therefore, this work highlights the discovery of a new and promising multi-target drug that, besides acting as an AI, appears to also act as an ERα antagonist and AR agonist. Thus, the multi-target action of Oxy may be a therapeutic advantage over the three AIs applied in clinic. Furthermore, this new multi-target compound has the ability to sensitize the AI-resistant BC cells, which represents another advantage over the endocrine therapy used in the clinic, since resistance is a major drawback in the clinic.
Open AccessAn Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER+) Breast Cancer: Effects on Sensitive and Resistant Cell Lines
Around 70–85% of all breast cancer (BC) cases are estrogen receptor-positive (ER+). The third generation of aromatase inhibitors (AIs) is the first-line treatment option for these tumors. Despite their therapeutic success, they induce several side effects and resistance, which limits their efficacy. Thus, it is crucial to search for novel, safe and more effective anti-cancer molecules. Currently, multi-target drugs are emerging, as they present higher efficacy and lower toxicity in comparison to standard options. Considering this, this work aimed to investigate the anti-cancer properties and the multi-target potential of the compound 1α,2α-epoxy-6-methylenandrost-4-ene-3,17-dione (Oxy), also designated by Oxymestane-D1, a derivative of Exemestane, which we previously synthesized and demonstrated to be a potent AI. For this purpose, it was studied for its effects on the ER+ BC cell line that overexpresses aromatase, MCF-7aro cells, as well as on the AIs-resistant BC cell line, LTEDaro cells. Oxy reduces cell viability, impairs DNA synthesis and induces apoptosis in MCF-7aro cells. Moreover, its growth-inhibitory properties are inhibited in the presence of ERα, ERβ and AR antagonists, suggesting a mechanism of action dependent on these receptors. In fact, Oxy decreased ERα expression and activation and induced AR overexpression with a pro-death effect. Complementary transactivation assays demonstrated that Oxy presents ER antagonist and AR agonist activities. In addition, Oxy also decreased the viability and caused apoptosis of LTEDaro cells. Therefore, this work highlights the discovery of a new and promising multi-target drug that, besides acting as an AI, appears to also act as an ERα antagonist and AR agonist. Thus, the multi-target action of Oxy may be a therapeutic advantage over the three AIs applied in clinic. Furthermore, this new multi-target compound has the ability to sensitize the AI-resistant BC cells, which represents another advantage over the endocrine therapy used in the clinic, since resistance is a major drawback in the clinic.
- 1 November 2021
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 537, 111426
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells
- 1 November 2021
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 537, 111426
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells
- 1 July 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 177, 113989
Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?
- 1 July 2020
- Published by Elsevier in Biochemical Pharmacology
- Vol. 177, 113989
Estrogen receptor-positive (ER+) breast cancer treatment: Are multi-target compounds the next promising approach?
- Open Access
- 30 October 2019
- Published by MDPI AG
A novel approach for ER+ breast cancer treatment: A new compound that modulates aromatase and ER
Introduction: Estrogen receptor-positive (ER+) breast cancer is the most common subtype of breast cancer worldwide. Estrogens, after being synthetized by aromatase, bind to ERα promoting breast cancer proliferation (1). Therefore, the therapies already approved act either by inhibiting aromatase or by modulating ERα. However, besides their therapeutic success, they induce several side effects (2), reason why it is crucial to discover novel therapeutic approaches. Aim: Considering that aromatase activity and ERα activation display important roles in this type of cancer, our goal is to discover multi-target compounds able to simultaneously inhibit aromatase and modulate ERα. Methods: We used the ChEMBL Database to retrieve all the known aromatase inhibitors (AIs) and ERα antagonists. Using the ChemAxon software we computed two types of chemical descriptors: extended connectivity fingerprints and the pharmacophore fingerprints of each compound. After this, clusters were constructed and the selected compounds were analyzed by molecular docking. Anti-aromatase activity was evaluated in human placental microsomes and ERα expression was assessed by Western-Blot in ER+ an aromatase-overexpressing breast cancer cell line (MCF-7aro). Results: Based on clusters and after docking studies one compound (MT1) was selected to be studied in microsomes and in MCF-7aro cells. Although MT1 binds to key residues in aromatase important for its inhibition, unexpectedly, MT1 was not able to inhibit this enzyme in microsomes. However, as Exemestane, the steroidal AI used in clinic (1), MT1 induced a decrease in aromatase protein levels in MCF-7aro cells. Furthermore, MT1 impaired ERα activation, acting as an ERα antagonist. Discussion: To the best of our knowledge, this is the first attempt to discover multi-target compounds for ER+ breast cancer, using this type of approach. In fact, the compound MT1 was able to modulate aromatase and ERα, two key targets of this type of cancer, which represents a great advantage over other molecules used in breast cancer treatment. Acknowledgments: The authors are grateful to Fundação para a Ciência e Tecnologia (FCT) for CA Post-doc grant (SFRH/BPD/98304/2013) and for the financial support (UID/MULTI/04378/2019). References: Amaral C, Varela CL, Mauricio J, Sobral AF, Costa SC, Roleira FMF, et al. Anti-tumor efficacy of new 7alpha-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells. J Steroid Biochem Mol Biol. 2017;171:218-28. 2. Augusto TV, Correia-da-Silva G, Rodrigues CMP, Teixeira N, Amaral C. Acquired resistance to aromatase inhibitors: where we stand! Endocr Relat Cancer. 2018;25(5):R283-R301.
- 30 October 2019
- Published by MDPI AG
Open AccessA novel approach for ER+ breast cancer treatment: A new compound that modulates aromatase and ER
Introduction: Estrogen receptor-positive (ER+) breast cancer is the most common subtype of breast cancer worldwide. Estrogens, after being synthetized by aromatase, bind to ERα promoting breast cancer proliferation (1). Therefore, the therapies already approved act either by inhibiting aromatase or by modulating ERα. However, besides their therapeutic success, they induce several side effects (2), reason why it is crucial to discover novel therapeutic approaches. Aim: Considering that aromatase activity and ERα activation display important roles in this type of cancer, our goal is to discover multi-target compounds able to simultaneously inhibit aromatase and modulate ERα. Methods: We used the ChEMBL Database to retrieve all the known aromatase inhibitors (AIs) and ERα antagonists. Using the ChemAxon software we computed two types of chemical descriptors: extended connectivity fingerprints and the pharmacophore fingerprints of each compound. After this, clusters were constructed and the selected compounds were analyzed by molecular docking. Anti-aromatase activity was evaluated in human placental microsomes and ERα expression was assessed by Western-Blot in ER+ an aromatase-overexpressing breast cancer cell line (MCF-7aro). Results: Based on clusters and after docking studies one compound (MT1) was selected to be studied in microsomes and in MCF-7aro cells. Although MT1 binds to key residues in aromatase important for its inhibition, unexpectedly, MT1 was not able to inhibit this enzyme in microsomes. However, as Exemestane, the steroidal AI used in clinic (1), MT1 induced a decrease in aromatase protein levels in MCF-7aro cells. Furthermore, MT1 impaired ERα activation, acting as an ERα antagonist. Discussion: To the best of our knowledge, this is the first attempt to discover multi-target compounds for ER+ breast cancer, using this type of approach. In fact, the compound MT1 was able to modulate aromatase and ERα, two key targets of this type of cancer, which represents a great advantage over other molecules used in breast cancer treatment. Acknowledgments: The authors are grateful to Fundação para a Ciência e Tecnologia (FCT) for CA Post-doc grant (SFRH/BPD/98304/2013) and for the financial support (UID/MULTI/04378/2019). References: Amaral C, Varela CL, Mauricio J, Sobral AF, Costa SC, Roleira FMF, et al. Anti-tumor efficacy of new 7alpha-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells. J Steroid Biochem Mol Biol. 2017;171:218-28. 2. Augusto TV, Correia-da-Silva G, Rodrigues CMP, Teixeira N, Amaral C. Acquired resistance to aromatase inhibitors: where we stand! Endocr Relat Cancer. 2018;25(5):R283-R301.
- Open Access
- 1 September 2017
- Published by Wolters Kluwer Health in Porto Biomedical Journal
- Vol. 2 (5) , 221-222
The effects of cannabinoids in exemestane-resistant breast cancer cells
- 1 September 2017
- Published by Wolters Kluwer Health in Porto Biomedical Journal
- Vol. 2 (5) , 221-222
Open AccessThe effects of cannabinoids in exemestane-resistant breast cancer cells